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To the Editor, Chronic bronchitis is characterized by inflammation, cough and increased mucus production.
There is no cure, and current treatment options are limited to addressing symptoms [1] . The RejuvenAir® System (CSA Medical, Inc., Lexington MA, USA) is a device designed to bronchoscopically address chronic bronchitis by delivering liquid nitrogen (LN 2 ) as a Metered Cryospray™ (MCS). MCS is controlled by a thermocouple on the delivery catheter that feeds back real time information regarding the amount of LN 2 being delivered. That amount is tailored such that each bronchial airway receives a standardized amount of LN 2 based on airway size leading to a 10mm circular cryoablationwith a depth between 0.1mm to 0.5mm.
Based on older generations LN 2 spray interventions [2, 3] , it is hypothesized that LN 2 can induce an airway tissue healing effect by destroying the hyperplastic goblet cells and excess submucous glands. The extracellular matrix facilitates rapid regrowth of normal epithelium without scarring, a hallmark of cryoablation [4, 5] . The healing resulting from LN 2 MCS is the basis of this proposed treatment.
To start this project, we evaluated the safety of delivering LN 2 in two small pilot studies. Two sprays were delivered into the lobar and first segmental bronchi, which would be the most distal extent of the anticipated airway treatment in chronic bronchitis, based on the significant goblet cell pathology present in these areas [6] . The primary endpoint for each study was the evaluation of device related serious adverse events (SAEs). The initial study (NCT02106143, previously reported as ATS-2016 conference abstract [7] ) was conducted in subjects who were scheduled to undergo lobectomy or pneumonectomy immediately following MCS. The second study (NCT02483052) evaluated the same initial, plus post procedure safety as these subjects had a planned lobectomy after MCS. Both studies had evaluation of potential histologic effects of MCS as a secondary endpoint and the specimens were reviewed by an independent pathologist skilled in cryothermic tissue injuries (JC). Procedures were performed by flexible bronchoscopy under general anesthesia using an endotracheal tube with positive pressure ventilation. During the LN 2 spray, the endotracheal tube was disconnected from the ventilator with the cuff deflated, both to allow N 2 gas egress. Major inclusion criteria included FEV 1 ≥50% of predicted, no bullae >3cm, and no previous lung surgery of any sort. Both studies were approved by the local ethics committees and all patients provided informed consent.
Overall, 16 subjects were enrolled and treated at 3 sites in Europe and Canada. The initial study Eight immediate resection subjects treated bronchial segments were available, with in five of them revealing presence of the intended cryothermic histologic changes. In the regions with greater epithelial changes, minimal to mild acute inflammation was present. In two specimens there was extension into the submucosa with cryothermic changes involving the submucosal glands with preservation of the underlying submucosal structure including no effect on underlying cartilage (figure 1).
In the delayed resection study, a bronchoscopy was performed just before lung resection took place. The video of these bronchoscopies were independently reviewed by an experienced In summary, the data obtained in both clinical trials met the primary and secondary endpoints with safe delivery of MCS to the segmental and/or lobar bronchi without device related serious adverse events. Histology from immediate resection specimens documented MCS effect, and non-scarring healed tissue from the delayed resection group.
The information learned from this study is important for the future development of a bronchoscopic treatment for patients who suffer from chronic bronchitis. While the future intended indication was not specifically studied in these patients, they share some chronic bronchitis characteristics such as exposure to cigarettes, and most having COPD. Using MCS in a similar population and determining the immediate and delayed healing response has provided important information in the stepwise clinical development of the system. These results warrant further investigation in a larger clinical trial targeting chronic bronchitis patients, which is currently underway (NCT02483637). 
Legend to the figures

Figure 2
Representative 14 days post liquid nitrogen metered cryospray treated bronchial micrograph demonstrating complete rejuvenative healing characterized by pseudostratified respiratory epithelium with occasional goblet cells, preservation of the submucosa and cartilage, and absence of inflammation and fibrosis (Hematoxylin and eosin stained, 400x magnification).
